Helius Therapeutics Partners with Novachem to Expand High-Quality NZ-Made GMP Medicinal Cannabis Products into Australia

Helius Therapeutics, New Zealand's largest and most advanced medicinal cannabis company, is thrilled to announce a strategic partnership with Novachem, a leading Australian distributor of medicinal cannabis products. This collaboration will see Novachem serve as the sponsor and primary distributor for a range of Helius Therapeutics’ New Zealand-grown, New Zealand-made, GMP-certified medicinal cannabis products in Australia, offering a wider range of product options for Australian patients.

Since 2021, Helius Therapeutics has been dedicated to providing high-quality medicinal cannabis products to Kiwi patients. The recent changes in New Zealand’s export regulations have created an exciting opportunity for the company to extend its reach beyond New Zealand’s borders. Our state-of-the-art production facilities and unwavering commitment to research, development, and GMP standards ensure that our products are crafted with the highest levels of safety and quality.

Carmen Doran, CEO of Helius Therapeutics, shared her enthusiasm for the partnership, stating, “Our expansion into Australia represents an important milestone for Helius Therapeutics. Partnering with Novachem aligns with our mission to deliver top-tier, GMP-certified products to a broader patient base. The recent regulatory changes have made this opportunity possible, and we are excited to bring our premium products to a new market. This collaboration will enable us to extend our reach and improve the lives of more patients in need of advanced medicinal cannabis treatments.”

This partnership marks a significant step forward for both Helius Therapeutics and Novachem. By combining our strengths, we are set to enhance the availability of premium medicinal cannabis products and advance the standards of care for Australian patients.